Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2001

View Archived Issues

Sonus updates recent achievements with three development products

Bristol-Myers Squibb highlights significant developments during 2000

Geron regains rights to telomerase inhibitors from Pharmacia; forms new division

Xenogen establishes two new license agreements

Highly potent, short peptide attenuates head trauma-associated mortality and brain damage

PBOX-6 shows potential for bypassing apoptotic suppressor Bcr-Abl in CML

Oxford BioMedica and AHP jointly develop novel antibody cancer therapy

Production, development of recombinant mammastatin planned by Biotherapies

IDEC-131 commences phase II trial for psoriasis

Increased ACR20 response rate reported with 5G1.1

BioChem Pharma reviews progress during the year

Enrollment begins in phase III trial of Leuprogel 4-month for prostate cancer

Zofenopril reaches market for two cardiovascular indications

Starlix, the first in a new class of agents for type 2 diabetes, recommended for E.U. approval

Cel-Sci/NCI CRADA renewed and expanded

New heterocyclic chemopreventive agents described in U.S. patent

Japanese scientists reveal new antiasthmatic series

Substituted benzodioxan, benzofuran or benzopyran derivatives useful for GI disorders

Novel anticoagulants synthesized and tested at Aventis

Inhibitors of JNK, compositions and methods of use described by Vertex team

Positive modulation of AMPA receptors achieved with new CoCensys compounds

Merck reports synthesis, use of new peptidomimetic protein prenyltransferase inhibitors

New antihistaminic/antiallergic agents designed by Almirall Prodesfarma

U.S. introduction of first-in-class antifungal agent for life-threatening infections imminent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...